Brendon Monahan

Brendon Monahan is a Professor at Monash University, affiliated with the Faculty of Pharmacy and Pharmaceutical Sciences and the Department of Drug Discovery Biology. He serves as the Director of MedChem Australia within the Monash Institute of Pharmaceutical Sciences (MIPS), leading multidisciplinary drug discovery programs with a focus on translating research into novel therapies. His work is highly collaborative, involving partnerships with CSIRO, WEHI, Peter MacCallum Cancer Centre, and other leading research institutions.

Research Interests: Brendon Monahan's research spans drug discovery, cancer biology, epigenetics, gene regulation, and translational medical research. He has made significant contributions to programs targeting epigenetic regulators such as KAT6A/B and TIP60, kinase signaling, RNA modulation, and immuno-oncology. His work has led to the licensing of drug discovery programs to major pharmaceutical companies, including Pfizer.

Publication Trends: His recent publications (2020–2023) emphasize the development of selective inhibitors for histone acetyltransferases, structural biology of therapeutic targets like ENPP1, and mechanisms of cell cycle arrest in cancer. These works reflect a strong focus on epigenetic drug discovery, structural pharmacology, and mechanistic cancer biology, with applications in breast cancer and senescence-inducing therapies.

Scientific Recognition: While specific awards are not listed, his research has been referenced in patents, picked up by news outlets, and widely shared on social media, indicating high impact and visibility in the scientific community.

Advising and Grants: Although no direct mention of students or grants is provided, his leadership roles and extensive collaborative output suggest involvement in mentoring and securing research funding. He has contributed to numerous high-impact, peer-reviewed publications, often in leading journals such as Cell Chemical Biology and Journal of Medicinal Chemistry.

Labs and Teams: As Director of MedChem Australia, he leads a major drug discovery initiative within MIPS, coordinating teams across structural biology, medicinal chemistry, and cancer pharmacology. His leadership in the former Cancer Therapeutics CRC (CTx) underscores his experience in managing large-scale, collaborative research consortia.